당 회사는 2026년 2월 23일 개최한 주주총회에서 상법 제418조 및 정관 8조, 제8조의 2, 제8조의 3, 제9조 제2항 제6호에 의거하여 제3자 배정방식에 의한 기명식 제1종 상환전환우선주식을 발행하기로 결의하였으므로 상법 제418조 제4항에 의하여 다음 사항을 공고합니다.
-다 음-
-
- 신주식의 종류와 수: 기명식 제1종 상환전환우선주식 28,621주
- 신주식의 발행가액: 1주당 금 314,400원
- 신주식의 청약 및 납입기일: 2026년 3월 12일
- 신주의 인수방법: 제3자배정방식(상법 제418조 및 정관 제9조 제2항 제6호)
- 현물출자를 하는 자의 성명과 그 목적인 재산의 종류, 수량, 가액과 이에 대하여 부여할 주식의 종류와 수: 해당사항 없음
- 주금납입처: 중소기업은행 반포지점 외
- 주금납입방법: 신주인수인은 주금을 주금납입처에 현금으로 납입하여야 한다.
2026년 2월 25일
셀로이드 주식회사
경상북도 포항시 남구 청암로 87, 6층 626호(지곡동, 체인지업 그라운드)
사내이사 김동성
On June 17, Korea Investment & Securities recognized Celloid as a potential game changer in the organoid market. Celloid is gaining significant attention for its innovative solutions.
The organoid industry is poised for rapid growth, driven by the expansion of the advanced regenerative medicine sector and regulatory shifts such as the U.S. FDA’s phased elimination of animal testing. Demand for organoids is rising as they become essential platforms for developing and validating regenerative therapies, and their adoption is expected to grow as a reliable alternative to animal testing.
With its proprietary technology enabling the stable production of high-quality organoids, Celloid is positioned to be a key player in this expanding market.
Go to link
Celloid has signed a MOU with EDmicBio, a company specializing in the development of 3D organ-on-a-chip systems using its own in-house 3D bioprinting technology.
This agreement represents a strategic open innovation model between two leading Korean biotech companies, centered around organoids and bioprinting—key technologies driving the future of the bioindustry. The collaboration aims to co-develop liver organoids by integrating liver tissue-derived bioink with automated 3D cell culture technology.
Dong Sung Kim, CEO of Celloid, was featured in an interview with BIOTIMES. Celloid’s groundbreaking 3D cell culture platform has started to gain attention in the advanced biotechnology industry.
Our innovative technology is enabling the scalable production of high-quality organoids with consistent reproducibility and relevance.
Go to link
Finally, our versatile 3D cell culture systems, OrgaNest® Basic+ with NestWell®, have been adopted at
-
Toxicological Research Division of National Institute of Food & Drug Safety Evaluation(NIFDS), Ministry of Food and Drug Safety(MFDS).
-
Seoul Asan Medical Center
How impressive! We are improving the system’s functionality by operating the currently installed equipment and generating valuable collaborative outcomes.
Celloid has signed a Memorandum of Understanding (MOU) with YiPSCELL, a company specializing in the development of regenerative therapies based on induced pluripotent stem cells (iPSCs).
Through this partnership, the two companies will collaborate on developing organoid-based regenerative therapies, with a particular focus on treatments for cartilage and liver diseases. Their goal is to provide personalized treatment solutions in the field of advanced regenerative medicine by leveraging 3D cell culture automation technology.
Go to link
Our versatile 3D cell culture systems, NestWell® and OrgaNest® Basic+, have been installed at the Stem Cell Convergence Research Center of KRIBB, Korea Research Institute of Bioscience and Biotechnology.
We are eager to explore the impressive collaborative research outcomes that our solutions can facilitate.
Dong Sung Kim, CEO of Celloid, delivered an impressive talk titled ‘Development of an Automated Cell Culture System for Organoid Standardization’ at the Joint Symposium on the Expansion of Biohealth Standardization Utilization, organized by the Korea Food and Drug Administration and the National Institute of Standards and Technology.
Go to link
Exciting news: the 3D cell culture system, “OrgaNest®,” has officially launched and is now installed at the Center for 3D Organ Printing and Stem Cells at POSTECH.
We eagerly await updates on the innovative research being conducted with OrgaNest® in Pohang!
Copyright by Celloid 2023. All rights reserved.
Copyright by Celloid 2023. All rights reserved.